Trutakna FDA Approval: Dual BAFF/APRIL Biologic for IgA Nephropathy
On July 7, 2026, the U.S. Food and Drug Administration granted accelerated approval to Trutakna (atacicept‑vymj), a once‑weekly subcutaneous biologic developed by Vera Therapeutics, Inc., to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN) who are at risk…
